What is the projected market valuation of the Blood Cancer Diagnostic Market by 2035?

The Blood Cancer Diagnostic Market is projected to reach a valuation of 16.08 USD Billion by 2035. Read More

What was the market valuation of the Blood Cancer Diagnostic Market in 2024?

In 2024, the Blood Cancer Diagnostic Market was valued at 7.547 USD Billion. Read More

What is the expected CAGR for the Blood Cancer Diagnostic Market during the forecast period 2025 - 2035?

The expected CAGR for the Blood Cancer Diagnostic Market during the forecast period 2025 - 2035 is 7.12%. Read More

Which companies are considered key players in the Blood Cancer Diagnostic Market?

Key players in the Blood Cancer Diagnostic Market include Roche, Abbott, Thermo Fisher Scientific, and Bristol-Myers Squibb. Read More

What are the projected revenues for blood tests in the Blood Cancer Diagnostic Market by 2035?

The projected revenue for blood tests in the Blood Cancer Diagnostic Market is expected to reach 5.5 USD Billion by 2035. Read More

How does the revenue from biopsies compare to that of imaging techniques in 2035?

By 2035, the revenue from biopsies is projected to be 4.5 USD Billion, whereas imaging techniques may reach 6.0 USD Billion. Read More

What is the expected revenue for diagnostic procedures in the Blood Cancer Diagnostic Market by 2035?

The expected revenue for diagnostic procedures in the Blood Cancer Diagnostic Market is projected to be 8.0 USD Billion by 2035. Read More

What segment of cancer type is projected to generate the highest revenue by 2035?

The segment for 'Other Blood Cancers' is projected to generate the highest revenue, reaching 5.58 USD Billion by 2035. Read More

What is the anticipated revenue for genetic sequencing technology in the Blood Cancer Diagnostic Market by 2035?

The anticipated revenue for genetic sequencing technology is expected to reach 7.0 USD Billion by 2035. Read More

How does the revenue from serum samples compare to that of plasma samples by 2035?

By 2035, the revenue from serum samples is projected to be 4.0 USD Billion, while plasma samples may reach 3.5 USD Billion. Read More

Blood Cancer Diagnostic Market

ID: MRFR/HC/29418-HCR

128 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Blood Cancer Diagnostic Market Research Report By Procedure (Blood Test, Biopsy, Imaging Techniques), By Stage of Diagnosis (Screening, Diagnostic, Prognostic), By Cancer Type (Leukemia, Lymphoma, Myeloma, Other Blood Cancers), By Sample Type (Whole Blood, Plasma, Serum, Bone Marrow Aspirate), By Technology Platform (Immunohistochemistry, Flow Cytometry, PCR, Genetic Sequencing) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Blood Cancer Diagnostic Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.12%

2024 Market Size$ 7.55 Billion

2025 Market Size$ 8.08 Billion

2035 Market Size$ 16.08 Billion

Key Players

Roche

Abbott

Thermo Fisher Scientific

Bristol-Myers Squibb

Novartis

Amgen

Trends

Technological Advancements in Diagnostics
Increased Focus on Early Detection
Regulatory Support for New Technologies

Opportunities

Rising Incidence of Blood Cancers
Growing Awareness and Education on Blood Cancer
Integration of Telemedicine in Diagnostic Services

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Procedure (USD Billion)
  1. 4.1.1 Blood Tests
  2. 4.1.2 Biopsies
  3. 4.1.3 Imaging Techniques
2. 4.2 Healthcare, BY Stage of Diagnosis (USD Billion)
  1. 4.2.1 Screening
  2. 4.2.2 Diagnostic
  3. 4.2.3 Prognostic
3. 4.3 Healthcare, BY Cancer Type (USD Billion)
  1. 4.3.1 Leukemia
  2. 4.3.2 Lymphoma
  3. 4.3.3 Myeloma
  4. 4.3.4 Other Blood Cancers
4. 4.4 Healthcare, BY Sample Type (USD Billion)
  1. 4.4.1 Whole Blood
  2. 4.4.2 Plasma
  3. 4.4.3 Serum
  4. 4.4.4 Bone Marrow Aspirate
5. 4.5 Healthcare, BY Technology Platform (USD Billion)
  1. 4.5.1 Immunohistochemistry
  2. 4.5.2 Flow Cytometry
  3. 4.5.3 PCR
  4. 4.5.4 Genetic Sequencing
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GSK (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Siemens Healthineers (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Illumina (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY PROCEDURE
4. 6.4 US MARKET ANALYSIS BY STAGE OF DIAGNOSIS
5. 6.5 US MARKET ANALYSIS BY CANCER TYPE
6. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE
7. 6.7 US MARKET ANALYSIS BY TECHNOLOGY PLATFORM
8. 6.8 CANADA MARKET ANALYSIS BY PROCEDURE
9. 6.9 CANADA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
10. 6.10 CANADA MARKET ANALYSIS BY CANCER TYPE
11. 6.11 CANADA MARKET ANALYSIS BY SAMPLE TYPE
12. 6.12 CANADA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY PROCEDURE
15. 6.15 GERMANY MARKET ANALYSIS BY STAGE OF DIAGNOSIS
16. 6.16 GERMANY MARKET ANALYSIS BY CANCER TYPE
17. 6.17 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY TECHNOLOGY PLATFORM
19. 6.19 UK MARKET ANALYSIS BY PROCEDURE
20. 6.20 UK MARKET ANALYSIS BY STAGE OF DIAGNOSIS
21. 6.21 UK MARKET ANALYSIS BY CANCER TYPE
22. 6.22 UK MARKET ANALYSIS BY SAMPLE TYPE
23. 6.23 UK MARKET ANALYSIS BY TECHNOLOGY PLATFORM
24. 6.24 FRANCE MARKET ANALYSIS BY PROCEDURE
25. 6.25 FRANCE MARKET ANALYSIS BY STAGE OF DIAGNOSIS
26. 6.26 FRANCE MARKET ANALYSIS BY CANCER TYPE
27. 6.27 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY TECHNOLOGY PLATFORM
29. 6.29 RUSSIA MARKET ANALYSIS BY PROCEDURE
30. 6.30 RUSSIA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
31. 6.31 RUSSIA MARKET ANALYSIS BY CANCER TYPE
32. 6.32 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
34. 6.34 ITALY MARKET ANALYSIS BY PROCEDURE
35. 6.35 ITALY MARKET ANALYSIS BY STAGE OF DIAGNOSIS
36. 6.36 ITALY MARKET ANALYSIS BY CANCER TYPE
37. 6.37 ITALY MARKET ANALYSIS BY SAMPLE TYPE
38. 6.38 ITALY MARKET ANALYSIS BY TECHNOLOGY PLATFORM
39. 6.39 SPAIN MARKET ANALYSIS BY PROCEDURE
40. 6.40 SPAIN MARKET ANALYSIS BY STAGE OF DIAGNOSIS
41. 6.41 SPAIN MARKET ANALYSIS BY CANCER TYPE
42. 6.42 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY TECHNOLOGY PLATFORM
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY PROCEDURE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY STAGE OF DIAGNOSIS
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY PLATFORM
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY PROCEDURE
51. 6.51 CHINA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
52. 6.52 CHINA MARKET ANALYSIS BY CANCER TYPE
53. 6.53 CHINA MARKET ANALYSIS BY SAMPLE TYPE
54. 6.54 CHINA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
55. 6.55 INDIA MARKET ANALYSIS BY PROCEDURE
56. 6.56 INDIA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
57. 6.57 INDIA MARKET ANALYSIS BY CANCER TYPE
58. 6.58 INDIA MARKET ANALYSIS BY SAMPLE TYPE
59. 6.59 INDIA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
60. 6.60 JAPAN MARKET ANALYSIS BY PROCEDURE
61. 6.61 JAPAN MARKET ANALYSIS BY STAGE OF DIAGNOSIS
62. 6.62 JAPAN MARKET ANALYSIS BY CANCER TYPE
63. 6.63 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY TECHNOLOGY PLATFORM
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY PROCEDURE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
70. 6.70 MALAYSIA MARKET ANALYSIS BY PROCEDURE
71. 6.71 MALAYSIA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
72. 6.72 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
73. 6.73 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
75. 6.75 THAILAND MARKET ANALYSIS BY PROCEDURE
76. 6.76 THAILAND MARKET ANALYSIS BY STAGE OF DIAGNOSIS
77. 6.77 THAILAND MARKET ANALYSIS BY CANCER TYPE
78. 6.78 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY TECHNOLOGY PLATFORM
80. 6.80 INDONESIA MARKET ANALYSIS BY PROCEDURE
81. 6.81 INDONESIA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
82. 6.82 INDONESIA MARKET ANALYSIS BY CANCER TYPE
83. 6.83 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
85. 6.85 REST OF APAC MARKET ANALYSIS BY PROCEDURE
86. 6.86 REST OF APAC MARKET ANALYSIS BY STAGE OF DIAGNOSIS
87. 6.87 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
88. 6.88 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY PLATFORM
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY PROCEDURE
92. 6.92 BRAZIL MARKET ANALYSIS BY STAGE OF DIAGNOSIS
93. 6.93 BRAZIL MARKET ANALYSIS BY CANCER TYPE
94. 6.94 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY TECHNOLOGY PLATFORM
96. 6.96 MEXICO MARKET ANALYSIS BY PROCEDURE
97. 6.97 MEXICO MARKET ANALYSIS BY STAGE OF DIAGNOSIS
98. 6.98 MEXICO MARKET ANALYSIS BY CANCER TYPE
99. 6.99 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY TECHNOLOGY PLATFORM
101. 6.101 ARGENTINA MARKET ANALYSIS BY PROCEDURE
102. 6.102 ARGENTINA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
103. 6.103 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
104. 6.104 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PROCEDURE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY PROCEDURE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY STAGE OF DIAGNOSIS
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY PLATFORM
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY PROCEDURE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
122. 6.122 REST OF MEA MARKET ANALYSIS BY PROCEDURE
123. 6.123 REST OF MEA MARKET ANALYSIS BY STAGE OF DIAGNOSIS
124. 6.124 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
125. 6.125 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY PLATFORM
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY PROCEDURE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY PROCEDURE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY STAGE OF DIAGNOSIS, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY STAGE OF DIAGNOSIS, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY TECHNOLOGY PLATFORM, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TECHNOLOGY PLATFORM, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.2.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.2.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.2.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.3.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.3.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.3.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.4.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.4.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.4.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.5.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.5.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.5.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.6.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.6.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.6.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.7.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.7.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.7.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.8.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.8.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.8.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.9.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.9.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.9.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.10.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.10.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.10.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.11.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.11.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.11.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.12.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.12.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.12.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.13.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.13.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.13.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.14.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.14.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.14.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.15.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.15.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.15.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.16.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.16.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.16.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.17.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.17.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.17.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.18.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.18.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.18.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.19.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.19.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.19.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.20.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.20.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.20.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.21.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.21.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.21.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.22.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.22.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.22.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.23.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.23.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.23.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.24.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.24.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.24.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.25.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.25.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.25.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.26.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.26.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.26.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.27.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.27.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.27.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.28.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.28.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.28.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.29.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.29.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.29.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY PROCEDURE, 2025-2035 (USD Billion)
  2. 7.30.2 BY STAGE OF DIAGNOSIS, 2025-2035 (USD Billion)
  3. 7.30.3 BY CANCER TYPE, 2025-2035 (USD Billion)
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.30.5 BY TECHNOLOGY PLATFORM, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Blood Cancer Diagnostic Market Segmentation

Blood Cancer Diagnostic Market By Procedure (USD Billion, 2025-2035)

Blood Tests
Biopsies
Imaging Techniques

Blood Cancer Diagnostic Market By Stage of Diagnosis (USD Billion, 2025-2035)

Screening
Diagnostic
Prognostic

Blood Cancer Diagnostic Market By Cancer Type (USD Billion, 2025-2035)

Leukemia
Lymphoma
Myeloma
Other Blood Cancers

Blood Cancer Diagnostic Market By Sample Type (USD Billion, 2025-2035)

Whole Blood
Plasma
Serum
Bone Marrow Aspirate

Blood Cancer Diagnostic Market By Blood Cancer Diagnostic Market Platform (USD Billion, 2025-2035)

Immunohistochemistry
Flow Cytometry
PCR
Genetic Sequencing

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”